Shanghai-based Unixell Biotechnology Co., Ltd. has announced that its Investigational New Drug (IND) application for “UX-DA001 Injection (Human Midbrain Dopaminergic Neuronal Precursor Cell Injection)” has been accepted by the Center for Drug Evaluation (CDE). The therapy, which aligns with the company’s inaugural pipeline, is speculated to target Parkinson’s disease.
Founded in 2021, Unixell is a biopharmaceutical company dedicated to the development of next-generation cell therapy drugs based on human pluripotent stem cell technology. Leveraging its proprietary platform for stem cell preparation, culture, differentiation, and gene editing, Unixell is committed to technological research and development and product development in the field of stem cell therapy. Its R&D pipeline spans neurodegenerative diseases, rare diseases, and oncology. Unixell has a solid foundation in cell therapy technology research, particularly achieving a world-class level in the research and development of neural system cell therapies, with multiple patents to its name.
On July 11th, Unixell announced the completion of a tens of millions of yuan Series A+ funding round, led by the State-owned Capital Venture Investment Fund. Following a Series A round of over 100 million yuan in April this year, the company has once again secured funding, highlighting the capital market’s high recognition of Unixell’s stem cell therapy technology. Kunlun Capital invested in Unixell in August 2021 and March 2022.- Flcube.com
